Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care
Amwell (NYSE: AMWL) has announced the addition of Vida Health to its clinical programs portfolio, expanding its virtual cardiometabolic care offerings. The new program, Amwell Cardiometabolic Care Powered by Vida, will provide obesity and diabetes care services, including GLP-1s and anti-obesity medications, through Amwell's platform to health plans and employers.
The program will offer personalized care considering social factors like food security, financial barriers, and cultural norms. Vida's services will integrate with Amwell's existing virtual primary care, urgent care, and behavioral health programs. The partnership aims to address the significant healthcare challenge of obesity, which affects over 40% of American adults and, combined with diabetes, costs the U.S. healthcare system more than $500 billion annually.
The collaboration focuses on delivering value-based, outcomes-driven care through lifestyle interventions and Medical Nutrition Therapy, providing members with a unified entry point for clinical and behavioral health support.
Amwell (NYSE: AMWL) ha annunciato l'aggiunta di Vida Health al suo portafoglio di programmi clinici, ampliando le sue offerte di assistenza cardiometabolica virtuale. Il nuovo programma, Amwell Cardiometabolic Care Powered by Vida, fornirà servizi per la cura dell'obesità e del diabete, inclusi i GLP-1 e i farmaci anti-obesità, attraverso la piattaforma di Amwell per piani sanitari e datori di lavoro.
Il programma offrirà assistenza personalizzata considerando fattori sociali come la sicurezza alimentare, le barriere economiche e le norme culturali. I servizi di Vida si integreranno con l'assistenza primaria virtuale, l'assistenza urgente e i programmi di salute comportamentale già esistenti di Amwell. La partnership mira ad affrontare la significativa sfida sanitaria dell'obesità, che colpisce oltre il 40% degli adulti americani e, combinata con il diabete, costa al sistema sanitario statunitense più di 500 miliardi di dollari all'anno.
La collaborazione si concentra sulla fornitura di assistenza basata sul valore e orientata ai risultati attraverso interventi sullo stile di vita e la Terapia nutrizionale medica, offrendo ai membri un punto di ingresso unificato per il supporto sanitario clinico e comportamentale.
Amwell (NYSE: AMWL) ha anunciado la incorporación de Vida Health a su cartera de programas clínicos, ampliando sus ofertas de atención cardiometabólica virtual. El nuevo programa, Amwell Cardiometabolic Care Powered by Vida, proporcionará servicios de atención para la obesidad y la diabetes, incluidos los GLP-1 y los medicamentos antiobesidad, a través de la plataforma de Amwell para planes de salud y empleadores.
El programa ofrecerá atención personalizada teniendo en cuenta factores sociales como la seguridad alimentaria, las barreras económicas y las normas culturales. Los servicios de Vida se integrarán con la atención primaria virtual, la atención urgente y los programas de salud conductual existentes de Amwell. La colaboración busca abordar el importante desafío sanitario de la obesidad, que afecta a más del 40% de los adultos estadounidenses y que, combinado con la diabetes, cuesta al sistema sanitario de EE. UU. más de 500 mil millones de dólares al año.
La colaboración se centra en ofrecer atención basada en el valor y orientada a resultados a través de intervenciones en el estilo de vida y la Terapia de Nutrición Médica, proporcionando a los miembros un punto de entrada unificado para el apoyo en salud clínica y conductual.
Amwell (NYSE: AMWL)는 Vida Health를 임상 프로그램 포트폴리오에 추가하여 가상 심혈관 대사 치료 제공 범위를 확장했다고 발표했습니다. 새로운 프로그램인 Amwell Cardiometabolic Care Powered by Vida는 Amwell의 플랫폼을 통해 건강 계획 및 고용주에게 비만 및 당뇨병 치료 서비스를 제공할 것입니다. 이 서비스는 GLP-1 및 항비만 약물을 포함합니다.
이 프로그램은 식량 안전, 경제적 장벽, 문화적 규범과 같은 사회적 요소를 고려하여 개인 맞춤형 치료를 제공합니다. Vida의 서비스는 Amwell의 기존 가상 1차 치료, 긴급 치료 및 행동 건강 프로그램과 통합됩니다. 이 파트너십의 목표는 40% 이상이 영향을 받는 미국 성인 중 비만으로 인한 중요한 건강 문제를 해결하는 것입니다. 비만과 당뇨병을 합치면 미국의 의료 시스템에 연간 5000억 달러 이상의 비용이 발생합니다.
이 협업은 생활 습관 개입과 의료 영양 요법을 통한 가치 기반의 결과 지향 치료 제공에 중점을 두며, 회원들에게 임상 및 행동 건강 지원을 위한 통합된 접근점을 제공합니다.
Amwell (NYSE: AMWL) a annoncé l'ajout de Vida Health à son portefeuille de programmes cliniques, élargissant ainsi ses offres de soins cardiométaboliques virtuels. Le nouveau programme, Amwell Cardiometabolic Care Powered by Vida, proposera des services de soins pour l'obésité et le diabète, y compris des GLP-1 et des médicaments anti-obésité, via la plateforme d'Amwell pour les régimes de santé et les employeurs.
Le programme offrira des soins personnalisés en tenant compte de facteurs sociaux tels que la sécurité alimentaire, les obstacles financiers et les normes culturelles. Les services de Vida s'intègreront aux soins primaires virtuels, aux soins urgents et aux programmes de santé comportementale existants d'Amwell. Le partenariat vise à relever le défi majeur de la santé lié à l'obésité, qui touche plus de 40 % des adultes américains et, combinée au diabète, coûte au système de santé américain plus de 500 milliards de dollars par an.
La collaboration se concentre sur la fourniture de soins basés sur la valeur et axés sur les résultats grâce à des interventions sur le mode de vie et à une Thérapie nutritionnelle médicale, offrant aux membres un point d'entrée unifié pour le soutien à la santé clinique et comportementale.
Amwell (NYSE: AMWL) hat die Hinzufügung von Vida Health zu seinem klinischen Programmportfolio angekündigt, um seine virtuell erbrachten kardiometabolischen Pflegeangebote zu erweitern. Das neue Programm Amwell Cardiometabolic Care Powered by Vida wird Dienste zur Betreuung von Adipositas und Diabetes anbieten, einschließlich GLP-1 und Anti-Adipositas-Medikamenten, über die Plattform von Amwell für Gesundheitspläne und Arbeitgeber.
Das Programm wird personalisierte Pflege anbieten, wobei soziale Faktoren wie Ernährungssicherheit, finanzielle Hürden und kulturelle Normen berücksichtigt werden. Die Dienste von Vida werden in die bestehenden virtuellen Primärversorgungs-, Notfall- und Verhaltensgesundheitsprogramme von Amwell integriert. Die Partnerschaft zielt darauf ab, die bedeutende Gesundheitsherausforderung von Adipositas zu bewältigen, die über 40% der amerikanischen Erwachsenen betrifft und in Kombination mit Diabetes das US-Gesundheitssystem jährlich mehr als 500 Milliarden Dollar kostet.
Die Zusammenarbeit konzentriert sich darauf, wertbasierte, ergebnisorientierte Pflege durch Lebensstilinterventionen und Medizinische Ernährungstherapie zu bieten und den Mitgliedern einen einheitlichen Zugangspunkt für klinische und verhaltensbezogene Gesundheitsunterstützung zu bieten.
- Integration expands Amwell's service offerings in the high-demand obesity and diabetes care market
- Addresses a $500 billion healthcare market opportunity
- Value-based, outcomes-driven model ensures accountability and measurable results
- Unified platform reduces member friction and improves accessibility to multiple healthcare services
- None.
Insights
This strategic partnership represents a pivotal expansion in Amwell's digital health ecosystem, particularly in the lucrative cardiometabolic care market. The integration of Vida Health into Amwell's platform creates a comprehensive care delivery system that addresses a
The partnership's value proposition centers on three key elements: First, the ability to prescribe GLP-1 medications through Vida's clinicians provides direct access to the rapidly growing weight loss drug market. Second, the integration creates a unified entry point for health plans, reducing administrative complexity and potentially increasing adoption rates. Third, the value-based pricing model aligns financial incentives with patient outcomes, which is particularly attractive to health plans and employers seeking cost-effective solutions.
The timing is strategic, coinciding with unprecedented demand for GLP-1s and rising obesity rates affecting
The integration of Vida's cardiometabolic services into Amwell's platform represents a calculated move to capitalize on the surging demand for GLP-1 medications and comprehensive weight management solutions. This partnership effectively positions Amwell to compete against other digital health players in the obesity management space, particularly as the GLP-1 market continues its explosive growth trajectory.
The value-based care model is particularly noteworthy as it aligns with healthcare payers' increasing focus on outcome-based reimbursement structures. By incorporating social determinants of health into their care delivery model, the program addresses a critical gap in traditional obesity treatment approaches, potentially leading to better engagement rates and improved outcomes.
For investors, this partnership could significantly expand Amwell's total addressable market and create new revenue opportunities through increased platform utilization and shared savings from improved health outcomes.
Vida to offer cardiometabolic solutions including GLP-1s and other anti-obesity medications on the Amwell platform
BOSTON and SAN FRANCISCO, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, today announced that Vida Health, a leader in virtual cardiometabolic care, is now part of the clinical programs portfolio on the Amwell platform.
The program, Amwell Cardiometabolic Care Powered by Vida, will be available to Amwell’s expansive client footprint of health plans and employers. Clients will be able to offer their members access to a suite of cardiometabolic care, including obesity, diabetes prevention and management, and behavioral health support. The program will tailor care based on social factors such as food security, financial barriers, cultural norms, and beliefs. Vida’s services are available on the Amwell platform alongside existing virtual primary care, urgent care, behavioral health and other clinical programs in the Amwell ecosystem.
“We are thrilled to partner with Amwell,” said Joe Murad, CEO of Vida Health. “By leveraging our complementary capabilities, we’re making it easier than ever to provide members with personalized, high-touch care. Together, we’re working to reduce member friction, improve health outcomes at scale, and reduce costs.”
More than 40 percent of American adults struggle with obesity, a condition that increases the risk of developing diabetes, heart disease and cancer. Together, obesity and diabetes cost the U.S. healthcare system more than
Vida clinicians prescribe GLP-1s, other anti-obesity medications and lifestyle interventions like Medical Nutrition Therapy. These services are delivered through a value-based, outcomes-driven model that ensures accountability and measurable results.
“We’re pleased Vida is joining the growing number of third-party programs available through Amwell’s integrated clinical solutions portfolio. With this partnership, our health plan clients can offer members a single entry point to the clinical and behavioral health support they need for obesity care and related illnesses,” said Ido Schoenberg, Amwell chairman and CEO. “Vida’s programs adapt to the patient’s needs, resulting in a personalized, cost-effective way to achieving weight loss requirements while applying an evidence-based, step therapy approach.”
Amwell’s clinical programs portfolio features virtual and digital care products from partners addressing various health conditions. The portfolio is part of the company’s platform and provides health plans with the technology to offer employers and members a unified and delightful entry point to a comprehensive and dynamic set of orchestrated clinical programs. The result is a personalized and reportable whole-person care model focused on improving health outcomes and driving efficiencies.
About Vida Health
Vida Health is a virtual obesity and metabolic center of excellence that provides personalized care for individuals with obesity and related conditions. Vida’s holistic approach combines human care with AI-powered insights to deliver lasting health outcomes and help prevent and manage chronic diseases. Vida serves members in all 50 states, offering services in both English and Spanish, and operates on a value-based pricing model, putting outcomes at the center of care. To learn more, visit www.Vida.com.
About Amwell
Amwell is a leading hybrid care delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2025 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Amwell ConvergeTM, CarepointTM and the Amwell logo are registered trademarks or trademarks of American Well Corporation.
FAQ
What new services will be available through AMWL's partnership with Vida Health?
How large is the market opportunity for AMWL's new cardiometabolic care program?
What unique features does AMWL's Cardiometabolic Care program powered by Vida offer?
How will AMWL's partnership with Vida Health benefit health plan clients?
